Assessment of patients' preferences for new anticancer drugs in China: a best-worst discrete choice experiment on three common cancer types.

Zhe FengJingyi MengYanjun SunTongling XieWenzhang LuGuohua WangJinsong Geng

Published in: BMJ open (2023)

Our study can assist in the implementation of SDM by providing evidence on patients' preferences for new anticancer drugs. Patients should be informed of the multiattribute values of new drugs and encouraged to make decisions reflecting their values.

Keyphrases

end stage renal disease
ejection fraction
newly diagnosed
chronic kidney disease
prognostic factors
squamous cell carcinoma
healthcare
young adults
patient reported outcomes
quality improvement